Moderna and Merck release melanoma vaccine trial data early

Moderna and Merck announced on Thursday that a personalized mRNA vaccine designed for melanoma patients lowered the risk of death or cancer recurrence by 42 percent compared to standard treatment in a late-stage clinical trial. The vaccine is intended for individuals whose melanoma has been surgically removed, and the announcement marks a significant step in the development of cancer treatments tailored to a patient's specific tumor profile. The companies stated that they are now engaging with regulatory authorities regarding potential approval of the vaccine.

Stéphane Bancel, CEO of Moderna, described the findings as a pivotal moment for the technology that the company has pursued. "From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient's tumor," Bancel said. The results "mark a defining moment for that vision and show what's possible when we rethink how medicines are made." He added that the data "reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer."

The decision to release these specific numbers now stems from an unexpected breach of an embargo. In August, the pharmaceutical partners indicated that the trial had met its goals but withheld detailed metrics, planning to unveil them at the European Society of Medical Oncology conference currently taking place in Madrid, Spain. The data was scheduled for presentation on Saturday. However, an oncology news site reported the figures before the scheduled release, prompting the companies to issue the top-line results early. The full set of data has been accepted for publication in the New England Journal of Medicine.

The trial in question was a Phase 3 study involving 1,137 patients diagnosed with stage IIB to IV melanoma whose tumors had already been removed through surgery prior to enrollment. Participants were randomly assigned in a two-to-one ratio to receive either the personalized mRNA vaccine in combination with a standard treatment, or the standard treatment on its own. The standard care provided in the control group was Merck's established monoclonal antibody treatment, Keytruda.

The release of these findings has fueled broader speculation regarding the potential of mRNA technology to provide a new paradigm for treating cancer. While the immediate focus remains on securing regulatory approval for this specific melanoma application, the success of the trial is viewed as a validation of individualized cancer-targeting medicines. The companies are preparing to present the full dataset to the scientific community to support the efficacy of the personalized approach.

Regulatory authorities will now review the data to determine if the vaccine can be approved for broader use. The companies have not provided a specific timeline for that review process. The scientific community awaits the full publication in the New England Journal of Medicine to scrutinize the details behind the reported 42 percent reduction in risk.